Fintel reports that on December 10, 2025, Oppenheimer upgraded their outlook for Dyne Therapeutics (NasdaqGS:DYN) from Perform to Outperform.
Analyst Price Forecast Suggests 92.56% Upside
As of December 6, 2025, the average one-year price target for Dyne Therapeutics is $35.51/share. The forecasts range from a low of $11.11 to a high of $52.50. The average price target represents an increase of 92.56% from its latest reported closing price of $18.44 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Dyne Therapeutics is 0MM. The projected annual non-GAAP EPS is -3.31.
What is the Fund Sentiment?
There are 415 funds or institutions reporting positions in Dyne Therapeutics. This is an decrease of 8 owner(s) or 1.89% in the last quarter. Average portfolio weight of all funds dedicated to DYN is 0.25%, an increase of 21.54%. Total shares owned by institutions increased in the last three months by 18.61% to 167,400K shares. 
The put/call ratio of DYN is 1.44, indicating a bearish outlook.
What are Other Shareholders Doing?
Janus Henderson Group holds 14,746K shares representing 10.32% ownership of the company. In its prior filing, the firm reported owning 9,438K shares , representing an increase of 35.99%. The firm decreased its portfolio allocation in DYN by 25.53% over the last quarter.
Atlas Venture Life Science Advisors holds 9,130K shares representing 6.39% ownership of the company. No change in the last quarter.
Fcpm Iii Services B.v. holds 5,463K shares representing 3.82% ownership of the company. No change in the last quarter.
Siren, L.L.C. holds 4,729K shares representing 3.31% ownership of the company. In its prior filing, the firm reported owning 4,836K shares , representing a decrease of 2.27%. The firm decreased its portfolio allocation in DYN by 2.66% over the last quarter.
TCG Crossover Management holds 4,615K shares representing 3.23% ownership of the company. In its prior filing, the firm reported owning 3,767K shares , representing an increase of 18.38%. The firm decreased its portfolio allocation in DYN by 29.88% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
